Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ba Wei Ai Gu Ning Granules is a traditional Chinese medicine (TCM) herbal formulation used in China. It is administered as granules and has been studied in the context of treating bone metastasis in lung cancer, as evidenced by a prospective multicenter randomized double-blind controlled study. The precise composition of the formula is not detailed in available English-language sources, but based on TCM naming conventions, "Ba Wei" indicates it contains eight herbal ingredients. The mechanism of action is presumed to be multi-targeted, typical for TCM formulas, potentially involving immunomodulation, anti-inflammatory effects, and support for organ function according to TCM theory. Its primary indication appears to be supportive care or adjunctive therapy for patients with bone metastases from lung cancer[1]. There are no details about its use outside clinical research settings or approval status outside China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ba Wei Ai Gu Ning Granules.